FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043580189> ?p ?o ?g. }

• W2043580189 endingPage "107" @default.
• W2043580189 startingPage "102" @default.
• W2043580189 abstract "Malignant pleural mesothelioma ( MPM ) is a rare and highly aggressive neoplasm that arises from the pleural, pericardial, or peritoneal lining. Although surgery, chemotherapy, radiotherapy, and combinations of these therapies are used to treat MPM , the median survival of such patients is dismal. Therefore, there is a compelling need to develop novel therapeutics with different modes of action. Ganglioside GM 2 is a glycolipid that has been shown to be overexpressed in various types of cancer. However, there are no published reports regarding the use of GM 2 as a potential therapeutic target in cases of MPM . In this study, we evaluated the efficacy of the anti‐ GM 2 antibody BIW ‐8962 as an anti‐ MPM therapeutic using in vitro and in vivo assays. Consequently, the GM 2 expression in the MPM cell lines was confirmed using flow cytometry. In addition, eight of 11 cell lines were GM 2‐positive (73%), although the GM 2 expression was variable. BIW ‐8962 showed a significant antibody‐dependent cellular cytotoxicity activity against the GM 2‐expressing MPM cell line MSTO ‐211H, the effect of which depended on the antibody concentration and effector/target ratio. In an in vivo orthotropic mouse model using MSTO ‐211H cells, BIW ‐8962 significantly decreased the incidence and size of tumors. Additionally, the GM 2 expression was confirmed in the MPM clinical specimens. Fifty‐eight percent of the MPM tumors were positive for GM 2, with individual variation in the intensity and frequency of staining. These data suggest that anti‐ GM 2 antibodies may become a therapeutic option for MPM patients." @default.
• W2043580189 created "2016-06-24" @default.
• W2043580189 creator A5001409378 @default.
• W2043580189 creator A5005918927 @default.
• W2043580189 creator A5017882443 @default.
• W2043580189 creator A5020746135 @default.
• W2043580189 creator A5022553135 @default.
• W2043580189 creator A5022815485 @default.
• W2043580189 creator A5035523274 @default.
• W2043580189 creator A5038749740 @default.
• W2043580189 creator A5054228512 @default.
• W2043580189 creator A5062271490 @default.
• W2043580189 creator A5069301897 @default.
• W2043580189 creator A5072708202 @default.
• W2043580189 creator A5081262580 @default.
• W2043580189 creator A5086218839 @default.
• W2043580189 creator A5091780654 @default.
• W2043580189 date "2014-12-18" @default.
• W2043580189 modified "2023-10-18" @default.
• W2043580189 title "Therapeutic activity of glycoengineered anti‐<scp>GM</scp>2 antibodies against malignant pleural mesothelioma" @default.
• W2043580189 cites W1607709966 @default.
• W2043580189 cites W1679485330 @default.
• W2043580189 cites W1895756316 @default.
• W2043580189 cites W1925567793 @default.
• W2043580189 cites W1964510242 @default.
• W2043580189 cites W1977376622 @default.
• W2043580189 cites W1981854366 @default.
• W2043580189 cites W1985102822 @default.
• W2043580189 cites W2013119704 @default.
• W2043580189 cites W2016896943 @default.
• W2043580189 cites W2042116436 @default.
• W2043580189 cites W2053155268 @default.
• W2043580189 cites W2094622791 @default.
• W2043580189 cites W2096763507 @default.
• W2043580189 cites W2100527196 @default.
• W2043580189 cites W2102627969 @default.
• W2043580189 cites W2122080125 @default.
• W2043580189 cites W2124505866 @default.
• W2043580189 cites W2131561057 @default.
• W2043580189 cites W2136470067 @default.
• W2043580189 cites W2140421188 @default.
• W2043580189 cites W2147877609 @default.
• W2043580189 cites W2160936126 @default.
• W2043580189 cites W2164756833 @default.
• W2043580189 cites W4298031624 @default.
• W2043580189 doi "https://doi.org/10.1111/cas.12575" @default.
• W2043580189 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4317781" @default.
• W2043580189 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25421609" @default.
• W2043580189 hasPublicationYear "2014" @default.
• W2043580189 type Work @default.
• W2043580189 sameAs 2043580189 @default.
• W2043580189 citedByCount "9" @default.
• W2043580189 countsByYear W20435801892016 @default.
• W2043580189 countsByYear W20435801892017 @default.
• W2043580189 countsByYear W20435801892018 @default.
• W2043580189 countsByYear W20435801892020 @default.
• W2043580189 countsByYear W20435801892022 @default.
• W2043580189 countsByYear W20435801892023 @default.
• W2043580189 crossrefType "journal-article" @default.
• W2043580189 hasAuthorship W2043580189A5001409378 @default.
• W2043580189 hasAuthorship W2043580189A5005918927 @default.
• W2043580189 hasAuthorship W2043580189A5017882443 @default.
• W2043580189 hasAuthorship W2043580189A5020746135 @default.
• W2043580189 hasAuthorship W2043580189A5022553135 @default.
• W2043580189 hasAuthorship W2043580189A5022815485 @default.
• W2043580189 hasAuthorship W2043580189A5035523274 @default.
• W2043580189 hasAuthorship W2043580189A5038749740 @default.
• W2043580189 hasAuthorship W2043580189A5054228512 @default.
• W2043580189 hasAuthorship W2043580189A5062271490 @default.
• W2043580189 hasAuthorship W2043580189A5069301897 @default.
• W2043580189 hasAuthorship W2043580189A5072708202 @default.
• W2043580189 hasAuthorship W2043580189A5081262580 @default.
• W2043580189 hasAuthorship W2043580189A5086218839 @default.
• W2043580189 hasAuthorship W2043580189A5091780654 @default.
• W2043580189 hasBestOaLocation W20435801891 @default.
• W2043580189 hasConcept C142724271 @default.
• W2043580189 hasConcept C150903083 @default.
• W2043580189 hasConcept C159654299 @default.
• W2043580189 hasConcept C203014093 @default.
• W2043580189 hasConcept C207001950 @default.
• W2043580189 hasConcept C2777407522 @default.
• W2043580189 hasConcept C502942594 @default.
• W2043580189 hasConcept C54355233 @default.
• W2043580189 hasConcept C553184892 @default.
• W2043580189 hasConcept C71924100 @default.
• W2043580189 hasConcept C81885089 @default.
• W2043580189 hasConcept C86803240 @default.
• W2043580189 hasConceptScore W2043580189C142724271 @default.
• W2043580189 hasConceptScore W2043580189C150903083 @default.
• W2043580189 hasConceptScore W2043580189C159654299 @default.
• W2043580189 hasConceptScore W2043580189C203014093 @default.
• W2043580189 hasConceptScore W2043580189C207001950 @default.
• W2043580189 hasConceptScore W2043580189C2777407522 @default.
• W2043580189 hasConceptScore W2043580189C502942594 @default.
• W2043580189 hasConceptScore W2043580189C54355233 @default.
• W2043580189 hasConceptScore W2043580189C553184892 @default.
• W2043580189 hasConceptScore W2043580189C71924100 @default.
• W2043580189 hasConceptScore W2043580189C81885089 @default.

• next